Management of Atopic Dermatitis: Clinical Utility of Ruxolitinib

Atopic dermatitis (AD) is a common chronic, pruritic inflammatory skin disease that profoundly impacts patients’ quality of life. As the first FDA-approved topical JAK inhibitor, ruxolitinib 1.5% cream represents a novel therapeutic topical agent for the treatment of AD. The objective of this review...

Descripción completa

Detalles Bibliográficos
Autores principales: Owji, Shayan, Caldas, Stella A, Ungar, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9617518/
https://www.ncbi.nlm.nih.gov/pubmed/36316998
http://dx.doi.org/10.2147/JAA.S342051
Descripción
Sumario:Atopic dermatitis (AD) is a common chronic, pruritic inflammatory skin disease that profoundly impacts patients’ quality of life. As the first FDA-approved topical JAK inhibitor, ruxolitinib 1.5% cream represents a novel therapeutic topical agent for the treatment of AD. The objective of this review is to summarize the efficacy and safety of ruxolitinib cream in patients with AD based on the available evidence. Overall, ruxolitinib cream demonstrated high efficacy and a favorable safety profile for treating atopic dermatitis.

Ejemplares similares